Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 65

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells: APR-246 in acute myeloid leukemia

Ali, Dina, Jönsson-Videsäter, Kerstin, Deneberg, Stefan, Bengtzén, Sofia, Nahi, Hareth, Paul, Christer, Lehmann, Sören·2011·European Journal of Haematology
DOI 10.1111/j.1600-0609.2010.01557.x
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1600-0609.2010.01557.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 39

  1. Haferlach, 2008, Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype, Leukemia, 22, 1539, 10.1038/leu.2008.143 · DOI
  2. Nahi, 2008, Mutated and non-mutated TP53 as targets in the treatment of leukaemia, Br J Haematol, 141, 445, 10.1111/j.1365-2141.2008.07046.x · DOI · Paper page
  3. Zache, 2008, PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53, Cell Oncol, 30, 411
  4. Nahi, 2006, PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion, Br J Haematol, 132, p, 10.1111/j.1365-2141.2005.05851.x · DOI
  5. Sherr, 1998, Tumor surveillance via the ARF-p53 pathway, Genes Dev, 12, 2984, 10.1101/gad.12.19.2984 · DOI · Paper page
  6. Andersson, 1992, KBM-3, an in vitro model of human acute myelomonocytic leukemia, Exp Hematol, 20, 361
  7. Fenaux, 1992, Mutations of the P53 gene in acute myeloid leukaemia, Br J Haematol, 80, 178, 10.1111/j.1365-2141.1992.tb08897.x · DOI
  8. Ishikawa, 2009, Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia, Eur J Haematol, 83, 90, 10.1111/j.1600-0609.2009.01261.x · DOI
  9. Möllgård, 2000, In vitro chemosensitivity testing in acute non lymphocytic leukemia using the bioluminescence ATP assay, Leuk Res, 24, 445, 10.1016/S0145-2126(00)00003-5 · DOI
  10. Haglund, 1994, Hairy cell leukemia is characterized by clonal chromosome abnormalities clustered to specific regions, Blood, 83, 2637, 10.1182/blood.V83.9.2637.2637 · doi:10.1182/blood.v83.9.2637.2637
  11. Cree, 1999, ATP-based tumor chemosensitivity testing: assisting new agent development, Anticancer Drugs, 10, 431, 10.1097/00001813-199906000-00001 · doi:10.1097/00001813-199906000-00001
  12. Kangas, 1984, Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro, Med Biol, 62, 338
  13. Rhedin, 1993, Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells, Leuk Res, 17, 271, 10.1016/0145-2126(93)90011-9 · doi:10.1016/0145-2126(93)90011-9
  14. van Stijn, 2003, A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia, Leukemia, 17, 780, 10.1038/sj.leu.2402885 · doi:10.1038/sj.leu.2402885
  15. Paul, 2009, Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival, Leuk Lymphoma, 50, 1512, 10.1080/10428190903111914 · DOI
  16. Fransen, 2004, Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas, Carcinogenesis, 25, 527, 10.1093/carcin/bgh049 · DOI · Paper page
  17. Möllgård, 2008, The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia, Cancer Chemother Pharmacol, 62, 439, 10.1007/s00280-007-0623-4 · doi:10.1007/s00280-007-0623-4
  18. Lepri, 1991, In vitro synergistic activity of PDN-IFN alpha and NM + IFN alpha combinations on fresh bone-marrow samples from multiple myeloma patients, Hematol Oncol, 9, 79, 10.1002/hon.2900090203 · DOI
  19. Campos, 1993, High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy, Blood, 81, 3091, 10.1182/blood.V81.11.3091.3091 · DOI · Paper page
  20. Zhang, 2009, [Neurotoxicity of beta-amyloid peptide 31-35 and 25-35 to cultured rat cortical neurons], Zhonghua Yu Fang Yi Xue Za Zhi, 43, 1081
  21. Valeriote, 1975, Synergistic interaction of anticancer agents: a cellular perspective, Cancer Chemother Rep, 59, 895
  22. Blandino, 1999, Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy, Oncogene, 18, 477, 10.1038/sj.onc.1202314 · DOI · Paper page
  23. Bossi, 2006, Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression, Oncogene, 25, 304, 10.1038/sj.onc.1209026 · DOI · Paper page
  24. Sigal, 2000, Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome, Cancer Res, 60, 6788
  25. Wiman, 2007, Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy, Adv Cancer Res, 97, 321, 10.1016/S0065-230X(06)97014-6 · DOI
  26. Stuber, 2009, PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein, Mol Cancer, 8, 23, 10.1186/1476-4598-8-23 · DOI
  27. Wattel, 1994, p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies, Blood, 84, 3148, 10.1182/blood.V84.9.3148.3148 · DOI · Paper page
  28. Schoch, 2005, Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile, Genes Chromosom Cancer, 43, 227, 10.1002/gcc.20193 · DOI · Paper page
  29. Zheng, 1999, p53 status of newly established acute myeloid leukaemia cell lines, Br J Cancer, 79, 407, 10.1038/sj.bjc.6690064 · DOI
  30. Lambert, 2010, Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis, Oncogene, 29, 1329, 10.1038/onc.2009.425 · DOI
  31. Lucken-Ardjomande, 2005, Regulation of Bcl-2 proteins and of the permeability of the outer mitochondrial membrane, C R Biol, 328, 616, 10.1016/j.crvi.2005.05.002 · DOI
  32. Miyashita, 1995, Tumor suppressor p53 is a direct transcriptional activator of the human bax gene, Cell, 80, 293, 10.1016/0092-8674(95)90412-3 · DOI · Paper page
  33. Del Poeta, 2003, Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML), Blood, 101, 2125, 10.1182/blood-2002-06-1714 · DOI · Paper page
  34. Prokop, 2000, Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo, Leukemia, 14, 1606, 10.1038/sj.leu.2401866 · DOI · Paper page
  35. Bothner, 2001, Defining the molecular basis of Arf and Hdm2 interactions, J Mol Biol, 314, 263, 10.1006/jmbi.2001.5110 · DOI
  36. Weber, 2000, Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex, Mol Cell Biol, 20, 2517, 10.1128/MCB.20.7.2517-2528.2000 · DOI · Paper page
  37. Oyan, 2009, Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia, BMC Cancer, 9, 77, 10.1186/1471-2407-9-77 · DOI
  38. Chou, 1996, Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro, Cancer Chemother Pharmacol, 37, 222, 10.1007/BF00688320 · DOI
  39. Nakano, 2001, PUMA, a novel proapoptotic gene, is induced by p53, Mol Cell, 7, 683, 10.1016/S1097-2765(01)00214-3 · DOI · Paper page

Cited by

See all 65

Metadata

Authors
Ali, D., Jönsson-Videsäter, K., Deneberg, S., Bengtzén, S., Nahi, H., Paul, C., & Lehmann, S.
Venue
European Journal of Haematology
Publisher
Wiley
Published
2011-01-11
Volume
86
Issue
3
Pages
206-215
ISSN
0902-4441
DOI
10.1111/j.1600-0609.2010.01557.x
Cited by
65
References
4
Language
en
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1694 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells: APR-246 in acute myeloid leukemia. https://app.cochat.ai/papers/10.1111/j.1600-0609.2010.01557.x
The paper
Ali, D., Jönsson-Videsäter, K., Deneberg, S., Bengtzén, S., Nahi, H., Paul, C., & Lehmann, S. (2011). APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells: APR-246 in acute myeloid leukemia. European Journal of Haematology. https://doi.org/10.1111/j.1600-0609.2010.01557.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.